Am. J. Respir. Crit. Care Med., Volume 162, Number 5, November 2000, 1767-1772

DNA and Actin Bind and Inhibit Interleukin-8 Function in Cystic Fibrosis Sputa
In Vitro Effects of Mucolytics

BEATRICE PERKS and JANIS K. SHUTE

Department of Medical Specialties, Southampton General Hospital, Southampton, United Kingdom

Infection of the cystic fibrosis (CF) airways elicits an exaggerated, interleukin-8 (IL-8) mediated, neutrophil inflammatory response. Necrosing neutrophils release DNA and actin into the airways, increasing the viscoelasticity of airway secretions. Mucolytics aim to improve airway clearance by reducing this viscoelasticity. DNase I reduces the viscoelasticity of CF sputum, and a human recombinant form of this enzyme is widely administered to patients with CF. Gelsolin, which cleaves actin polymers, is also known to reduce CF sputum viscosity in vitro, and it has been proposed as a future mucolytic agent. We have shown that the anionic polymers DNA and actin bind and mask immunologic recognition of the basic peptide IL-8 and prevent this chemokine from binding to neutrophil receptors. Reduction of CF sputum viscosity by DNase I or gelsolin in vitro was demonstrated to increase the proportion of free IL-8 and the IL-8-dependent neutrophil chemotactic activity of sputum supernatants. We hypothesize that an electrostatic interaction between polymer and chemokine may limit the inflammatory potential of the latter, but that this interaction may be weakened by polymer cleavage. The potential risk of increased inflammation via this mechanism suggests a caveat should be attendant on treatment of patients with CF with these mucolytic agents.

This article has been cited by other articles:

				Q. M. Parks, R. L. Young, K. R. Poch, K. C. Malcolm, M. L. Vasil, and J. A. Nick Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy J. Med. Microbiol., April 1, 2009; 58(4): 492 - 502. [Abstract] [Full Text] [PDF]

				K J Mackerness, G R Jenkins, A Bush, and P J Jose Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum Thorax, July 1, 2008; 63(7): 614 - 620. [Abstract] [Full Text] [PDF]

				V. J. Broughton-Head, J. Shur, M. P. Carroll, J. R. Smith, and J. K. Shute Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1240 - L1249. [Abstract] [Full Text] [PDF]

				R. Bucki, F. J. Byfield, and P. A. Janmey Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum Eur. Respir. J., April 1, 2007; 29(4): 624 - 632. [Abstract] [Full Text] [PDF]

				A. Bush, D. Payne, S. Pike, G. Jenkins, M. O. Henke, and B. K. Rubin Mucus Properties In Children With Primary Ciliary Dyskinesia: Comparison With Cystic Fibrosis Chest, January 1, 2006; 129(1): 118 - 123. [Abstract] [Full Text] [PDF]

				G. Candiano, M. Bruschi, N. Pedemonte, E. Caci, S. Liberatori, L. Bini, C. Pellegrini, M. Vigano, B. J. O'Connor, T. H. Lee, et al. Gelsolin Secretion in Interleukin-4-treated Bronchial Epithelia and in Asthmatic Airways Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1090 - 1096. [Abstract] [Full Text] [PDF]

				J. X. Tang, Q. Wen, A. Bennett, B. Kim, C. A. Sheils, R. Bucki, and P. A. Janmey Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L599 - L605. [Abstract] [Full Text] [PDF]

				T. S. Walker, K. L. Tomlin, G. S. Worthen, K. R. Poch, J. G. Lieber, M. T. Saavedra, M. B. Fessler, K. C. Malcolm, M. L. Vasil, and J. A. Nick Enhanced Pseudomonas aeruginosa Biofilm Development Mediated by Human Neutrophils Infect. Immun., June 1, 2005; 73(6): 3693 - 3701. [Abstract] [Full Text] [PDF]

				K. Paul, E. Rietschel, M. Ballmann, M. Griese, D. Worlitzsch, J. Shute, C. Chen, T. Schink, G. Doring, S. van Koningsbruggen, et al. Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 719 - 725. [Abstract] [Full Text] [PDF]

				D. J. Weiner, R. Bucki, and P. A. Janmey The Antimicrobial Activity of the Cathelicidin LL37 Is Inhibited by F-actin Bundles and Restored by Gelsolin Am. J. Respir. Cell Mol. Biol., June 1, 2003; 28(6): 738 - 745. [Abstract] [Full Text] [PDF]

				F Ratjen, C-M Hartog, K Paul, J Wermelt, and J Braun Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha Thorax, November 1, 2002; 57(11): 930 - 934. [Abstract] [Full Text] [PDF]

				R. Suri, L. J. Marshall, C. Wallis, C. Metcalfe, A. Bush, and J. K. Shute Effects of Recombinant Human DNase and Hypertonic Saline on Airway Inflammation in Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 352 - 355. [Abstract] [Full Text] [PDF]

				Leader of the Working Group: M.M. Kelly, Members of the Working Group:, V. Keatings, R. Leigh, C. Peterson, J. Shute, P. Venge, and R. Djukanovic Analysis of fluid{-}phase mediators Eur. Respir. J., July 1, 2002; 20(37_suppl): 24S - 39s. [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]